Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study

Abstract Background Inflammatory breast cancer (IBC) is an aggressive and highly angiogenic disease. Eribulin is a microtubule inhibitor with anti-angiogenic properties. Methods In a phase II trial, we examined the efficacy of an eribulin-containing neoadjuvant regimen (eribulin- > doxorubicin pl...

Full description

Bibliographic Details

Published in:	Breast Cancer Research
Main Authors:	Kristina Fanucci, Eren D. Yeh, Ruichao Shi, Lei Qin, Camden P. Bay, Molly DiLullo, Ashka Patel, McKenna Moore, Zachary T. Herbert, Beth T. Harrison, Faina Nakhlis, Jennifer Bellon, Laura Warren, Jennifer L. Guerriero, Sara M. Tolaney, Meredith Regan, Beth Overmoyer, Steven Van Laere, Filipa Lynce
Format:	Article
Language:	English
Published:	BMC 2025-09-01
Subjects:	Eribulin Doxorubicin Cyclophosphamide Neoadjuvant therapy HER2-negative Inflammatory Breast Cancer
Online Access:	https://doi.org/10.1186/s13058-025-02108-4